Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.

This hypothesis-driven trial is the first to indicate the possible pathogenic role of the Th2 axis and Th2 targeting in AA patients. Patient selection based on baseline serum IgE levels may improve treatment results (Clinicaltrials.gov number, NCT03359356).